文献速递临床试验与 GCP

PRECIOUS试验:预防老年急性卒中并发症改善预后的统计分析计划

PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke-statistical analysis plan of a randomised, open, phase III, clinical trial with blinded outcome assessment.
PubMed 文献 · Trials · 2020-10-26

PRECIOUS是一项国际多中心3×2析因随机开放标签盲法评估的III期临床试验,纳入老年急性卒中患者,评估卒中后4天内分别使用甲氧氯普胺、头孢曲松、对乙酰氨基酚预防误吸、感染或发热或其组合能否改善90天功能结局。本文为数据锁定与揭盲前撰写的统计分析计划,提供统计方法描述及空表图。试验前瞻性注册于ISRCTN82217627。

要点

  • 老年急性卒中患者卒中后早期常见误吸、感染和发热,与死亡或依赖风险增加相关。
  • PRECIOUS采用3×2析因设计,评估三种预防药物单独或联合对90天功能结局的影响。
  • 本文为统计分析计划,在数据锁定和揭盲前撰写,确保分析预先设定。

核心结论

  • PRECIOUS试验旨在评估预防误吸、感染或发热能否改善老年急性卒中患者90天功能结局。

研究设计与样本

  • 国际多中心、3×2析因、随机、对照、开放标签、盲法评估的III期临床试验。
  • 在卒中发病后4天内分别给予甲氧氯普胺、头孢曲松、对乙酰氨基酚或任意组合,评估90天功能结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Aspiration, infections, and fever are common in the first days after stroke, especially in older patients. The occurrence of these complications has been associated with an increased risk of death or dependency. AIMS AND DESIGN: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke (PRECIOUS) is an international, multi-centre, 3 × 2 factorial, randomised, controlled, open-label clinical trial with blinded outcome assessment, which will assess whether prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, respectively, or any combination of these in the first 4 days after stroke onset improves functional outcome at 90 days in elderly patients with acute stroke. DISCUSSION: This statistical analysis plan provides a technical description of the statistical methodology and unpopulated tables and figures. The paper is written prior to data lock and unblinding of treatment allocation. TRIAL REGISTRATION: ISRCTN registry ISRCTN82217627 . Registered on 22 September 2015. The trial was prospectively registered.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. de Jonge JC, Woodhouse LJ, Reinink H, et al. PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke-statistical analysis plan of a randomised, open, phase III, clinical trial with blinded outcome assessment. Trials. 2020. PMID: 33106180. doi:10.1186/s13063-020-04717-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。